2012
Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.
Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. The Yale Journal Of Biology And Medicine 2012, 85: 45-58. PMID: 22461743, PMCID: PMC3313539.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderPrefrontal cortexCognitive disordersHigher-order cognitive abilitiesDeficit hyperactivity disorderPFC cognitive functionCognitive abilitiesHyperactivity disorderCognitive functionMemory functionPFC functionAgonist guanfacineBrain regionsGuanfacineRecent researchNeurobiologyYale Medical SchoolCentury of discoveryDisordersTherapeutic targetTourette syndromePostsynaptic spinesEmotionsMemorySyndrome
2010
The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder
Arnsten A. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Review Of Neurotherapeutics 2010, 10: 1595-1605. PMID: 20925474, PMCID: PMC3143019, DOI: 10.1586/ern.10.133.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderPrefrontal cortexHyperactivity disorderPFC functionPFC gray matterPFC pyramidal cellsPyramidal cell networksDorsolateral prefrontal cortexPFC connectionsReceptors inhibitsPyramidal cellsAdrenergic agonistsDendritic spinesVentromedial prefrontal cortexGray matterRelated disordersBrain regionsNeuropsychiatric disordersPotassium channelsDisordersPatientsRecent dataPhysiological connectionTreatmentExecutive functioning
2009
5.3 Dopamine’s Influence on Prefrontal Cortical Cognition: Actions and Circuits in Behaving Primates
Arnsten A, Vijayraghavan S, Wang M, Gamo N, Paspalas C. 5.3 Dopamine’s Influence on Prefrontal Cortical Cognition: Actions and Circuits in Behaving Primates. 2009, 230-248. DOI: 10.1093/acprof:oso/9780195373035.003.0016.Peer-Reviewed Original Research
2005
Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder
Arnsten A. Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder. 2005, 183-iv. DOI: 10.1016/b978-012738903-5/50012-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderPrefrontal cortexTourette syndromeTherapeutic actionUse of guanfacineΑ2-adrenoceptor agonistNeuropsychiatric symptomsAppropriate medicationNeuromodulatory effectsTourette patientsPostsynaptic sitesNeurochemical environmentNeuropsychiatric illnessBrain circuitsSyndromePFC regulationBasic neuroscienceMolecular pharmacologyMolecular targetsDisordersGuanfacinePatientsPFC functionTreatment
1998
Catecholamine modulation of prefrontal cortical cognitive function
Arnsten A. Catecholamine modulation of prefrontal cortical cognitive function. Trends In Cognitive Sciences 1998, 2: 436-447. PMID: 21227275, DOI: 10.1016/s1364-6613(98)01240-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderPrefrontal cortexCognitive functionPrefrontal cortical cognitive functionUncontrollable stressCortical cognitive functionsWorking Memory FunctionDeficit hyperactivity disorderHyperactivity disorderPFC functionPFC dysfunctionNormal agingCognitive disordersCatecholamine modulationDopamine systemNeurochemical influencesMental disordersNeuropsychiatric disordersDisordersEnvironmental cuesCuesNeuromodulatory inputsMemoryFresh understandingHigh levels
1997
Catecholamine regulation of the prefrontal cortex
Arnsten A. Catecholamine regulation of the prefrontal cortex. Journal Of Psychopharmacology 1997, 11: 151-162. PMID: 9208378, DOI: 10.1177/026988119701100208.Peer-Reviewed Original ResearchConceptsPrefrontal cortexAdrenergic receptorsAlpha-1 adrenergic receptorsPFC functionPFC cognitive functionAlpha 2A-adrenergic receptorD1 receptor stimulationTreatment of disordersCatecholamine regulationCatecholamine releaseDA stimulationCatecholamine stimulationD2 familyProminent symptomReceptor stimulationModulatory influencePFC dysfunctionCognitive functionSubcortical structuresReview evidenceDetrimental actionsCatecholamines dopamineReceptorsStimulationNorepinephrineNoradrenergic Influences on Prefrontal Cortical Cognitive Function: Opposing Actions at Postjunctional α1 Versus α2-Adrenergic Receptors
Arnsten A, Steere JC, Jentsch DJ, Li BM. Noradrenergic Influences on Prefrontal Cortical Cognitive Function: Opposing Actions at Postjunctional α1 Versus α2-Adrenergic Receptors. Advances In Pharmacology 1997, 42: 764-767. PMID: 9328010, DOI: 10.1016/s1054-3589(08)60859-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPrefrontal cortexNE releaseΑ2 receptorsCognitive impairmentBeneficial effectsPFC functionBasal NE releasePrefrontal cortical cognitive functionΑ2-adrenergic receptorsCortical cognitive functionsPotential cognitive enhancersAttention deficit hyperactivity disorderMemory functionDeficit hyperactivity disorderPostsynaptic α1Α1d subtypesNE terminalsΑ-adrenoceptorsΑ2 agonistsLithium medicationNoradrenergic influenceOpen trialLithium pretreatmentΑ2A subtypeΑ2A receptors